When was OncoC4 founded?

OncoC4 was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is OncoC4 located?

OncoC4 is headquartered in Rockville, United States.

Who is the current CEO of OncoC4?

Yang Liu of OncoC4. They have also founded 1 company.

How many employees does OncoC4 have?

As of Sep 30, 2026, the latest employee count at OncoC4 is 69.

Is OncoC4 a funded company?

OncoC4 is a funded company, having raised a total of $50M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 03, 2020.

When was the latest funding round of OncoC4?

OncoC4's latest funding was a $***** Series B round on Oct 02, 2025, with participation from 3 investors.

Where does OncoC4 rank among its competitors?

OncoC4 ranks 116th amongst 3633 active competitors, of which 1187 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of OncoC4?

OncoC4's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

OncoC4 - 2026 Company Profile, Team, Funding & Competitors

OncoC4 is a series B company based in Rockville (United States), founded in 2020 by Yang Liu and Pan Zheng. It operates as a Developer of immunotherapy for cancer patients. OncoC4 has raised $50M in funding from GBA Fund. The company has 3633 active competitors, including 1187 funded and 817 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.

Website: oncoc4.com/en/
Email ID: *****@oncoc4.com

Key Metrics

Founded Year

2020

Location

Rockville, United States

Stage

Series B

Total Funding

$50M in 2 rounds

Latest Funding Round

Series B, Oct 02, 2025, $*****

Investors

GBA Fund & 5 more

Ranked

116^th among 3633 active competitors

Employee Count

69 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3275 more

View OncoC4's full profile

OncoC4 has raised a total funding of $50M over 2 rounds. Its first funding round was on Apr 03, 2020. Its latest funding round was a Series B round on Oct 02, 2025 for $*****. 3 investors participated in its latest round. OncoC4 has 6 institutional investors.

Here is the list of recent funding rounds of OncoC4:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 02, 2025	1602596	Series B	8157412	8191631	6770792	2568442
Apr 03, 2020	8356979	Grant (prize money)	5947911	6904877	6392530	HHS

Access funding benchmarks and valuations. Sign up today!

View details of OncoC4's funding rounds and investors

The founders of OncoC4 are Yang Liu and Pan Zheng. Yang Liu is the CEO of OncoC4.

Here are the details of OncoC4's key team members:

Yang Liu: Co-Founder & CEO & CSO & Chairman of OncoC4.
Pan Zheng: Co-Founder & Chief Medical Officer of OncoC4.
Contact Info: 1 email address

View details of OncoC4's Founder profiles and Board Members

OncoC4's employee count trend

OncoC4 has 69 employees as of Sep 26. Here is OncoC4's employee count trend over the years:

Uncover OncoC4's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of OncoC4 include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of OncoC4, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
116th	OncoC4 2020, Rockville (United States), Series B	Developer of immunotherapy for cancer patients	$50M	3E Bioventures Capital, HM Capital & 4 others	62/100